News
What's happening in Alzheimer's care, research funding, and treatment — summarized simply, each item linked to the original reporting.
Free to read, “May need a subscription” and “Archived copy”: what they mean
Whether an article is free to read is a guess, not a test of your access. Each item is one of three:
- No label: free to read (303 of 347). The publisher’s page marks it free, or the outlet publishes free to read: Medical Xpress, ScienceDaily, NIH (incl. NIA and PMC), Alzheimer's Association, Alzheimer's News Today, NPR, Alzheimer's Disease International, or a .gov site.
- May need a subscription (11 of 347). The publisher’s own page marks the article as not free to read, or — when the page says nothing — the outlet sells subscriptions: The New York Times, STAT, Scientific American, The Washington Post, The Wall Street Journal, Financial Times, The Economist, Bloomberg, The Atlantic, The New Yorker, Wired, Los Angeles Times, The Boston Globe, The Times, The Telegraph, New Scientist, Endpoints News, Science. Each badge says which.
- “Free to read? Not known” (33 of 347). The outlet is on neither list and its page said nothing. We do not call these paywalled.
Archived copy links go to a copy the Internet Archive (web.archive.org) saved, dated the day it was saved. We show one only where the Internet Archive reported a working saved copy when we checked; an archived copy of a subscription article sometimes shows only its opening. 265 of 347 items have one.
Cholesterol transport protein emerges as possible target for Parkinson's treatment
Parkinson's disease (PD) is a neurodegenerative condition that causes the progressive loss of dopamine-producing neurons in a brain region called the substantia nigra. Its characteristic symptoms include tremors, slowed movements, rigid muscles and difficulties with balance.
Read at Medical Xpress →Scientists discover new Alzheimer’s drug that repairs DNA damage and reduces brain inflammation
Scientists have discovered that a drug originally developed for spinal cord injuries can tackle several key features of Alzheimer’s disease, including DNA damage and inflammation. …
Read at ScienceDaily →Review board improves access to anti-amyloid therapies
SAN DIEGO — As demand increases for anti-amyloid therapy that can slow the progression of Alzheimer’s disease, it will be crucial for healthcare systems to find more efficient ways to review referrals for treatment, according to a presenter. …
Free to read? Not known for this outlet.
Read at Healio →Wireless neural chip tracks brain changes in real time after Alzheimer's drug administration
A joint research team led by KAIST has used a small, implantable neural chip to wirelessly monitor real-time changes in a neurotransmitter involved in memory and learning after an Alzheimer's drug has been administered. …
Read at Medical Xpress →Treatment revives old liver cells in lab study, may help prevent Alzheimer's and heart disease
The liver's job of clearing harmful substances from the body is so essential that the organ may have implications for addressing unexpected diseases, including Alzheimer's and heart disease. …
Read at Medical Xpress →Experimental treatment selectively reduces harmful protein in lab models of rare inherited brain disorder
Researchers from DZNE and the Hertie Institute for Clinical Brain Research (HIH) at the University of Tübingen, together with experts from Bonn, London and Portugal…
Read at Medical Xpress →Search for Alzheimer's drug unexpectedly finds possible biomarker
Researchers developed a drug for Alzheimer's disease and then discovered that the molecule already exists in human blood and is found at lower levels in cognitively impaired people. Now the authors are exploring the peptide as a biomarker as well as a treatment.
Read at Medical Xpress →Brain PET scans help select and monitor patients for new Alzheimer's drugs
Nuclear medicine is playing an increasingly important role in the diagnosis and treatment of Alzheimer's disease, helping clinicians visualize the biological changes associated with the condition and guide decisions about new therapies. …
Read at Medical Xpress →New drug-delivery method offers promise in fight against neurodegenerative diseases
For patients battling neurodegenerative diseases like ALS, Parkinson's, Alzheimer's and other dementias, delivering disease-fighting antibody drugs directly to the brain has proven to be a difficult task. …
Read at Medical Xpress → Archived copy (25 Oct 2026), Internet ArchiveWho gets Alzheimer's drugs? Race, vulnerability and health status shape access
The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients have the same opportunity to receive these treatments.
Alzheimer's Drug ARIA Monitoring: Real-World Study Results
(MedPage Today) -- Rates of amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease patients treated with lecanemab (Leqembi) in the real world were consistent with those seen in clinical trials, data from the LEADER study showed....
Free to read? Not known for this outlet.
Read at MedPage Today → Archived copy (17 Oct 2026), Internet ArchiveDrug combination that reduces oxygen levels in tissues improves Parkinson's symptoms in mice
In a new study, Broad Institute researchers report that two small-molecule chemicals that reduce oxygen delivery to cells improved symptoms of neurodegeneration in a mouse model of Parkinson's disease. …
Read at Medical Xpress →The hidden math of Alzheimer's could point to new treatments
Mathematics may hold unexpected clues to understanding Alzheimer’s disease. Scientists have developed a model showing how common metals like copper and zinc may influence the buildup of proteins associated with the disease, while also exploring possible ways to stop…
Read at ScienceDaily → Archived copy (12 Oct 2026), Internet ArchiveStarting Alzheimer's treatment earlier increases benefits to patients and society
New treatments that can slow the progression of Alzheimer's disease could provide significant lifetime benefits to patients and society, with even greater benefits when initiated earlier, according to new research from the USC Schaeffer Center for Health Policy & Economics.
Read at Medical Xpress → Archived copy (7 Oct 2026), Internet ArchiveClinical trial tests AI-assisted medication device for older adults with memory loss
Marianne Blake has lived in the same home for nearly half a century. She plays bridge regularly, drives to her hair appointments and, at 88 years old, enjoys her independence.
Read at Medical Xpress →STAT+: Nobel-winning optogenetics research has led to experimental treatments for blindness and Alzheimer’s
Optogenetics is now the foundational way through which we are able to understand how the brain…
Why it matters: Optogenetics research has led to experimental treatments for blindness and Alzheimer's, serving as a foundational way to understand brain function.
May need a subscription Based on the outlet (STAT), not a check of this article.
Read at STAT News → Archived copy (5 Oct 2026), Internet ArchiveDrugs are widely used to sedate dementia patients. Her sons wanted to keep her off them
Potent sedating medications are often used on agitated people with dementia in long-term care facilities despite federal efforts to discourage them. A clash over whether to drug a Michigan woman illuminates the wrenching decisions families and guardians face.
Why it matters: A Michigan dispute over sedating a woman with dementia shows the difficult decisions families face as care facilities widely use potent sedatives despite federal discouragement.
Read at NPR → Archived copy (8 Oct 2026), Internet ArchiveGene editing approach opens potential new route to Alzheimer's treatment
Dr. Kevin Kemp and his research team at the University of Bristol have converted the high-risk Alzheimer's gene APOE4 into the lower-risk APOE3 gene.
Read at Medical Xpress → Archived copy (29 Sep 2026), Internet ArchiveCan hormone replacement therapy prevent dementia? What the latest research tells us
A study has raised a question that many women would understandably want answered: Could hormone replacement therapy (HRT) protect against dementia? …
Why it matters: A study raised a key question about whether hormone replacement therapy (HRT) could help protect women against dementia.
Read at Medical Xpress →Blood proteins shift during Alzheimer's treatment and may help monitor the effects of the medication
Patients with early symptoms of Alzheimer's disease may be prescribed anti-amyloid therapy, which can help clear the sticky clumps of amyloid protein in the brain that characterize Alzheimer's. …
Why it matters: Shifts in blood proteins during Alzheimer's treatment may help monitor the effects of medication in patients receiving anti-amyloid therapy.
At-home injection version of Alzheimer’s drug now available in US
In the U.S., people with early Alzheimer’s disease will now have the option for at-home treatment with the approved therapy Leqembi (lecanemab) throughout the entire treatment journey. …
Read at Alzheimer's News Today → Archived copy (2 Oct 2026), Internet ArchiveFDA Clears C2N Diagnostics' PrecivityAD2 — First Alzheimer's Blood Test for Adults With Cognitive Symptoms as Young as 40
The FDA cleared C2N Diagnostics' PrecivityAD2 mass-spectrometry blood test for adults as young as 40 with signs of cognitive impairment, showing 97.6% positive predictive value and 93.1% negative predictive value for amyloid pathology in a 1,142-person study.
Why it matters: Extends FDA-cleared blood testing to younger patients with early symptoms, broadening options beyond the Fujirebio test and expanding access to earlier, less invasive diagnosis.
Free to read? Not known for this outlet.
Read at C2N Diagnostics (via BioSpace) → Archived copy (7 Oct 2026), Internet ArchiveFDA designation may speed new treatment for Alzheimer’s psychosis
The U.S. Food and Drug Administration (FDA) has granted fast track designation to remlifanserin, an experimental treatment that Acadia Pharmaceuticals is developing for hallucinations and delusions associated with Alzheimer’s disease psychosis. …
Read at Alzheimer's News Today →Lab-grown mini brains may predict which Alzheimer’s treatments will work
Miniature brain models grown from patients’ cells revealed striking differences in how Alzheimer’s-related tissue responds to an antidepressant. …
Read at ScienceDaily → Archived copy (1 Oct 2026), Internet ArchiveNew Alzheimer's drug repairs DNA damage and reduces brain inflammation
A drug originally developed for spinal cord injury may offer a fresh approach to treating Alzheimer’s disease. In mouse studies, KCL-286 repaired dangerous DNA damage, reduced inflammation…
Read at ScienceDaily → Archived copy (17 Jul 2026), Internet ArchiveStudy reports Alzheimer’s treatment gains in long-term care
Top-line data from a real-world study suggest that Zunveyl (benzgalantamine) was associated with provider-reported improvements in cognition, behavioral symptoms, daily functioning, and overall treatment experience in people with mild-to-moderate Alzheimer’s disease. …
Read at Alzheimer's News Today → Archived copy (12 Jul 2026), Internet ArchiveScientists reprogram brain immune cells to fight Alzheimer’s
A newly identified molecule called OLE helped restore the brain’s immune cells to a more protective state in Alzheimer’s models. The treatment reduced toxic plaque buildup and improved memory, raising hopes for a new therapeutic approach.
Read at ScienceDaily →Copper drug clears toxic Alzheimer’s proteins and restores memory
A copper-based compound restored the brain’s ability to clear toxic Alzheimer’s proteins, dramatically reducing amyloid buildup and improving memory in laboratory experiments. …
Read at ScienceDaily → Archived copy (20 Sep 2026), Internet ArchiveScientists found a new Alzheimer’s trigger and a drug that stops it
Researchers have identified a new Alzheimer’s target and created an experimental compound that blocks a damaging process inside brain cells. In mice, the treatment slowed nerve cell loss, reduced Alzheimer’s-related changes, and even appeared to promote healthier aging.
Read at ScienceDaily → Archived copy (23 Sep 2026), Internet ArchiveAlzheimer’s drugs may not work and could raise brain risks
Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually help patients in any meaningful way, according to a major review of over 20,000 participants. …
Follow new items in a feed reader: Atom feed.